Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007
To test the hypothesis of the SPY772 program, the company also announced the initiation of SKYLIGHT, a randomized Phase 2 proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F in Hidradenitis
Spyre Therapeutics is testing a new medicine that blocks two different disease-causing proteins at the same time to treat a painful skin condition. When a company starts testing a promising new idea in patients, it shows the company is moving forward—watch to see if the early results are good.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.